January 09, 2025
Florida-based Catalyst Pharmaceuticals Inc. has reached a settlement with Teva in a patent infringement battle in New Jersey federal court over its U.S. flagship commercial drug that treats a rare autoimmune disease that will provide Teva with a license to market a generic version of the drug in 2035, the company announced Thursday.
March 02, 2023
Florida-based Catalyst Pharmaceuticals Inc. has launched a series of patent infringement suits in federal courts against pharmaceutical companies relating to a drug that treats a rare autoimmune disease.